drugset
Drugs / TQB2102
last change 25 days ago re-read 9 days ago

TQB2102

also known as TQB2102 for injection

Monoclonal antibody targets ERBB2 via inhibition

Developed for
breast cancer · HER2 positive breast carcinoma · triple-negative breast carcinoma · biliary tract cancer · cancer of unknown primary site · carcinoma · female breast carcinoma · female reproductive system neoplasm
+4 more · gastroesophageal adenocarcinoma · hormone receptor-positive breast cancer · neoplasm · non-small cell lung carcinoma
Investigated by
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Fudan University · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Henan Cancer Hospital

Trials 18

today NCT07419880 · Ph 2 NCT07512583 · Ph 1/2 NCT07483684 · Ph 3 NCT07043725 · Ph 3 NCT07136974 · Ph 2 NCT07008976 · Ph 3 NCT07003074 · Ph 3 NCT06798207 · Ph 2 NCT06767800 · Ph 2 NCT06452706 · Ph 2 NCT06561607 · Ph 3 NCT06496490 · Ph 2 NCT06431490 · Ph 1/2 NCT06198751 · Ph 2 NCT06115902 · Ph 1 NCT05749588 · Ph 2 NCT05735496 · Ph 1 NCT05582499 · Ph 2
2023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06115902 Nov 2023 → Feb 2025 breast cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT05735496 Mar 2023 → Jul 2025 overdue cancer of unknown primary site Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07512583 May 2026 → Mar 2028 expected neoplasm Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06431490 Jul 2024 → May 2027 expected biliary tract cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 29 trials · 1 met primary
Phase 2 NCT07419880 Jan → Dec 2027 expected triple-negative breast carcinoma Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07136974 Sep 2025 → Aug 2028 expected HER2 positive breast carcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06798207 Mar 2025 → May 2026 overdue female reproductive system neoplasm Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06767800 Nov 2024 → Sep 2026 overdue gastroesophageal adenocarcinoma Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06452706 Nov 2024 → Jun 2026 overdue breast cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06496490 Aug 2024 → Jun 2026 overdue non-small cell lung carcinoma Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06198751 Feb 2024 → May 2025 overdue breast cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Active not recruiting Met primary
Phase 2 NCT05749588 Mar 2023 → Dec 2027 expected triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 2 NCT05582499 Nov 2022 → Dec 2027 expected HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 35 trials
Phase 3 NCT07483684 Mar 2026 → Aug 2027 expected carcinoma Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07043725 Sep 2025 → Sep 2027 expected HER2 positive breast carcinoma Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07008976 Jul 2025 → Mar 2028 expected breast cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07003074 Jun 2025 → Jul 2029 expected breast cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT06561607 Oct 2024 → Jan 2027 expected breast cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Active not recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 5

DateIssuerRelease
2026-09-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Regulatory 肿瘤、自免双线突破！正大天晴TQB2102、TQH2722上市申请同日获受理 cttq.com ↗
日前，中国生物制药（01177.HK）核心企业正大天晴开发的2款1类治疗用生物制品——注射用TQB2102及TQH2722注射液的上市申请同日被受理，分别用于既往在复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达（IHC 1+或IHC 2+/ISH-）成人乳腺癌患者，及治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎（AD）。
2025-07-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Regulatory 正大天晴双抗ADC药物TQB2102拟纳入突破性治疗品种 cttq.com ↗
近日，正大天晴自主研发的双特异性抗体偶联药物（ADC）注射用TQB2102被国家药监局药品审评中心（CDE）拟纳入突破性治疗品种，拟用于 HER2 阳性早期或局部晚期乳腺癌患者的新辅助治疗。
2025-06-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results 总病理完全缓解率73.1%，全球领先！TQB2102引领HER2阳性乳腺癌新辅助治疗再上新高度 cttq.com ↗
8周期治疗组整体的tpCR率达73.1%，其中6mg/kg队列达76.9% ，7.5mg/kg队列达69.2%。
2025-05-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results 正大天晴首款ADC数据首发：HER2双表位靶向ADC 核心技术助力临床突破 cttq.com ↗
仅出现1例2级ILD（0.55%），发生率远低于同类药物。
2025-05-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Results “国药之光”领衔12大ORAL刷屏ASCO，中国生物制药引领中国创新药企冲刺全球新 cttq.com ↗
TQB2102为中国生物制药自主开发的创新一代HER2双表位靶向ADC药物，本研究为TQB2102一期临床研究数据。

All press releases naming this drug 5 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as TQB2102 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06561607 ↗
17

NCT07419880 ↗

NCT06767800 ↗

NCT07008976 ↗

NCT06431490 ↗

NCT06452706 ↗

NCT06115902 ↗

NCT06198751 ↗

NCT06496490 ↗

NCT07043725 ↗

NCT05582499 ↗

Show 7 more sources
Known as TQB2102 for injection “TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.” NCT06198751 ↗
2

“TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)” NCT06115902 ↗

“TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)” NCT06431490 ↗
Action Inhibit “TQB2102: an anti-HER2 antibody-drug conjugate (ADC)” NCT05749588 ↗
Modality Monoclonal antibody “an anti-HER2 ADC” NCT05582499 ↗
Route Intravenous “intravenous infuse TQB2102 injection every three weeks, 21 days as a treatment cycle.” NCT05735496 ↗
Target ERBB2 “TQB2102: an anti-HER2 antibody-drug conjugate (ADC)” NCT05749588 ↗